Source: BioPortfolio

Promedior: . Roche to Expand Fibrotic Disease Pipeline with Upto$1.4B Promedior Acquisition httpow.lyKtqf50xckJMÂpic.twitter.comSu1vfk07BS

. Roche to Expand Fibrotic Disease Pipeline with Upto$1.4B Promedior Acquisition httpow.lyKtqf50xckJM pic.twitter.comSu1vfk07BS

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Estimated Annual Revenue

Estimated Employees

Jason Lettmann's photo - CEO of Promedior

CEO

Jason Lettmann

CEO Approval Rating

90/100

Promedior is a clinical-stage biotechnology company that develops and commercializes novel therapeutics for the treatmen... Read more